% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

biogemfinder 5 posts  |  Last Activity: May 13, 2016 1:43 PM Member since: Oct 25, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • $6.30 is what will be the key resistance. Something has changed as far as the traders,investors, hedge-funds and overall wall street calculations regarding EXEL is concerned. The added short interest will likely act as fuel to propel the stock price higher in coming months and years. Again, $20 is achievable this year if the sales go as expected , EU approval and celestial yields positive results in liver cancer. After that, $50 $60 in 3-4 yrs time-frame.

    Sentiment: Strong Buy

  • biogemfinder by biogemfinder May 9, 2016 1:57 PM Flag

    not a technician here but if we go past 5.40 area we are in the reassuring area. There may be another push before the close, but the penny pinchers are already selling their stocks to take a few pennies in gains.

    EXEL is a clinical and commercial stage companies. Things can only go up from here..more approvals, and increase in sales quarter after quarter fro many years to come. Speculative trade will fade away to be replaced by value investors and revenues and profits will determine the ultimate price. methinks..if done properly, Cabo has the potential to be very effective against prostate as well. Comets were badly designed and rushed. Once they have the resources, they need to go back to the frontlines as a combo with something else...its not that it did not work (PFS) was great, but OS wasn't good because of the patient population. Head to head with SOC, cabo would fare well

    20 BYE, and 50-100 in 3-5 years if the liver trial pans out and sales of Cabo and Cobi pick up reasonably well. Have waited for more than 10 years and not letting any of my shares part just yet!!

  • I have a feeling that the earnings numbers have been leaked to the ba$tids in WS and they have been selling or shorting ever sinc. It started form last hour of trading yesterday and continues. When will this POS managment know how to manage confidential data and make PRs at the right time? They always seem to not miss an oppotunity to miss an opportunity.

  • Reply to

    FDA...Wake up..Please swallow your Stubborn Pride!

    by pearsby09 Apr 29, 2016 11:24 AM
    biogemfinder biogemfinder Apr 29, 2016 2:16 PM Flag

    If FDA disregards its own rules of well controlled and sufficiently powered studies to approve drugs based on anecdotes and public opinions, then there is no need for its existence. In fact anyone can start making drugs and market and sell them.

    If the drug is effective, try selling it as a supplement, like thousands of weight loss drugs and others over the counter supplements. Why wait for FDAs blessing? If it is effective..people will pay for it right?

    If the FDA does grant approval in this case, then drug companies will change their strategy of running huge and expensive trials and just rely on emotions of patients. Emotions don't usually translate into good science or practice. The drug company is free to provide this drug to patients who "believe" in it in a compassionate basis and perhaps raise funds to do so. Nothing wrong with it, but to ask FDA to approve it and declare that this is efficacious based on anecdotal data without proper controls and size is wrong and unethical.

  • Another hack against EXEKL. It looks like the "Team Fool" has decided to pee onm any of EXEL's parade of good news. Lat time they compared Bristol vs EXEL and now Roche vs EXEL. Given the type of arguments these pukes put forward then there is no point in investin gin smaller and non-profitable companies because there is so much risk. If you take this argument further then you should just invest in SPY or other broad market indices and not speculate or do any kind of research. Pathetic attempt by fool;s to serfe their master from short hedge funds and the warrant holders like Deerfield. Dont listen to these fools. They have an agenda here.

6.15+0.15(+2.50%)May 24 4:00 PMEDT